Professional
Added to YB: 2019-01-15
Pitch date: 2019-01-15
HEMA [bullish]
HemaCare Corporation
+182.48%
current return
Author Info
Founder of Smoak Capital who shares analysis on stocks on Twitter and in his fund letter. Follow on Twitter.
Company Info
HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States.
Market Cap
$346.5M
Pitch Price
$8.96
Price Target
N/A
Dividend
N/A
EV/EBITDA
N/A
P/E
50.39
EV/Sales
N/A
Sector
Health Care Providers and Services
Category
growth
Smoak Capital holding: Hemacare
HEMA: Ex-blood bank pivoted to cell therapy market, serving pharma R&D. 5yr rapid growth into profitable, cash-rich biz. Leverages donor pool for specialized cells. Cell therapies show promise in cancer treatment. Strong mgmt execution, frugal spending. Upside from industry tailwinds & customer relationships despite higher valuation.
Read full article (1 min)